iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRadimed excels in Q4 2022, anticipates strong growth in 2023

IRadimed's Q4 2022 showcased exceptional performance with record revenues and strong earnings, setting the stage for continued growth.
While facing challenges such as margin pressures and tax expenses, the company's optimistic outlook for 2023 presents growth opportunities.
Strategic focus on revenue expansion, margin improvement, and cost management will be key to sustaining profitability and maximizing shareholder value.
Investors can look forward to potential earnings growth and market positioning strength in the upcoming year.

IRadimed reports record revenue and earnings growth, anticipates FDA clearance

IRadimed's Q1 2023 performance was strong, with record revenue and earnings growth. Despite supply chain challenges, the company is optimistic about FDA clearance for a new product and expects pricing trends to remain favorable.

iRadimed posts record revenue and earnings, raises guidance optimistically

iRadimed delivered exceptional financial performance in Q2 2023, achieving record revenue and substantial earnings growth, driven by strong sales across all product categories.
The company's operational efficiency, margin expansion, and strategic initiatives position it well for sustained growth and profitability in the future.
With raised guidance, innovative product developments, and expanding market presence, iRadimed is poised for continued success and value creation for shareholders.
Investors can be optimistic about iRadimed's performance, as the company demonstrates resilience, growth potential, and a solid foundation for future expansion.

iRadimed reports record Q3 earnings, raises 2023 guidance optimistically

iRadimed (IRMD) delivered exceptional Q3 '23 results, with record revenue, earnings growth, and strong product sales, positioning the company for continued success.
While facing challenges in meeting Q4 '23 targets and securing regulatory approvals, iRadimed's proactive strategies and market opportunities offer avenues for sustained growth.
With raised guidance for 2023 and promising product developments, iRadimed has the potential to capitalize on its strengths and navigate industry challenges effectively.
Investors and stakeholders can look to iRadimed's performance, product innovation, and regulatory progress as indicators of the company's resilience and growth prospects.

iRadimed (IRMD) reports record Q4 revenue, eyes international expansion

iRadimed's Q4 2023 performance marked by record revenue, strong device sales, and margin challenges. The company's focus on product growth and international expansion presents opportunities for future revenue and earnings growth.

iRadimed (IRMD) posts record revenue and earnings growth in Q1 2024

iRadimed (IRMD) delivered strong financial performance in Q1 2024, driven by record revenue, earnings growth, and robust demand for MR patient monitor products.
Despite challenges such as submission delays and significant investment in a new facility, the company remains focused on innovation and shareholder value.
With opportunities for market expansion, product clearance, and operational enhancements, iRadimed is poised for continued growth and competitive strength in the medical device industry.

iRadimed (IRMD) achieves record Q2 earnings, eyes FDA clearance

iRadimed's Q2 2024 performance reflects robust revenue growth, improved margins, and enhanced operational efficiency, positioning the company for continued success.
While facing challenges in international sales and operational delays, iRadimed's focus on cost management and product development presents opportunities for future growth.
Overall, iRadimed's financial outlook remains positive, with strong cash flow, new product developments, and strategic initiatives driving long-term value for investors.

iRadimed posts record Q3 earnings, eyes new product launches

iRadimed's Q3 2024 performance reflects strong revenue growth, operational efficiency, and effective cost management.
While facing challenges in product clearance and sales transition, the company is well-positioned to capitalize on growth opportunities.
Strategic focus on new product launches and international market expansion could drive future revenue and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates

WINTER SPRINGS, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces First Quarter 2022 Financial Results

WINTER SPRINGS, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resigned from the Company effective May 27, 2022. Mr. Scott started at the Company in December 2013 and is departing to pursue other opportunities.

IRADIMED CORPORATION Announces Executive Transition

WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2022 First Quarter Financial Results Conference Call on April 29th

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in iRadimed (IRMD) Should Keep going

Here is how iRadimed (IRMD) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?

Amphastar Pharma

Builders FirstSource

Choice Hotels Int.

Commercial Metals

Gladstone Investment

NAPCO Security Technologies

When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential. The post 7 Safe Stocks to Rely On When the Market Swerves appeared first on InvestorPlace.

7 Safe Stocks to Rely On When the Market Swerves

WINTER SPRINGS, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company's outstanding common stock. This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of business on February 17, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices. It produces the only known non-magnetic intravenous (“IV”) infusion pump system, and a non-magnetic patient vital signs monitoring system that is designed for use during MRI procedures.

IRADIMED Announces Special $1.00 Per Share Cash Dividend

IRadimed Corporation (IRMD) CEO Roger Susi on Q4 2021 Results - Earnings Call Transcript

iRadimed Corporation IRMD reported Q4 FY21 sales of $11.87 million, up 39% Y/Y, beating the consensus of $11.63 million. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why iRadimed Shares Are Surging Today?

WINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) --  iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months and year ended December 31, 2021.

IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results

WINTER SPRINGS, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 fourth quarter financial results before the market opens on Friday, February 4th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2021 Fourth Quarter Financial Results Conference Call on February 4th

A10 Networks

Insteel Industries

Navios Maritime Partners

Perion Network

Ryerson Hld

We've seen big tech rule the markets for a while, but now quality small-caps stocks are likely to begin stealing the headlines. The post 7 Excellent Small-Cap Stocks to Buy Before 2022 appeared first on InvestorPlace.

7 Excellent Small-Cap Stocks to Buy Before 2022

Here's Why "Trend" Investors Would Love Betting on iRadimed (IRMD)

iRadimed (IRMD) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook iRadimed (IRMD)

IRadimed's (IRMD) CEO Roger Susi on Q3 2021 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 35.29% and 4.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates

WINTER SPRINGS, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three and nine months ended September 30, 2021.

IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth

WINTER SPRINGS, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens on Friday, October 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2021 Third Quarter Financial Results Conference Call on October 29th

IRadimed Corporation (IRMD) CEO Roger Susi on Q2 2021 Results - Earnings Call Transcript

WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three and six months ended June 30, 2021.

IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results

IRadimed (IRMD) Earnings Expected to Grow: Should You Buy?

iRadimed (IRMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

iRadimed (IRMD) Stock Jumps 11.3%: Will It Continue to Soar?

WINTER SPRINGS, Fla., July 07, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 second quarter financial results before the market opens on Friday, July 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

News for iRadimed Stock (IRMD)